Meningococcal ACWY Conjugate Vaccine + DTaP-IPV-HBV + Hib + Rotavirus + Pneumococcal 7-valent Conjugate Vaccine + HAV + MMR-V + DTaP
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Meningitis, Meningococcal
Conditions
Meningitis, Meningococcal
Trial Timeline
Mar 1, 2007 → Nov 1, 2009
NCT ID
NCT00474526About Meningococcal ACWY Conjugate Vaccine + DTaP-IPV-HBV + Hib + Rotavirus + Pneumococcal 7-valent Conjugate Vaccine + HAV + MMR-V + DTaP
Meningococcal ACWY Conjugate Vaccine + DTaP-IPV-HBV + Hib + Rotavirus + Pneumococcal 7-valent Conjugate Vaccine + HAV + MMR-V + DTaP is a phase 3 stage product being developed by Novartis for Meningitis, Meningococcal. The current trial status is completed. This product is registered under clinical trial identifier NCT00474526. Target conditions include Meningitis, Meningococcal.
What happened to similar drugs?
8 of 20 similar drugs in Meningitis, Meningococcal were approved
Approved (8) Terminated (0) Active (12)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00474526 | Phase 3 | Completed |
Competing Products
20 competing products in Meningitis, Meningococcal